TUSSIONEX PENNKINETIC
LOE ApproachingNDAORALSUSPENSION, EXTENDED RELEASE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TUSSIONEX PENNKINETIC is an extended-release oral suspension combining hydrocodone (semisynthetic narcotic antitussive) and chlorpheniramine (antihistamine) for cough suppression. The Pennkinetic delivery system extends drug release via ion-exchange polymer matrix and diffusion-limiting coating, achieving peak hydrocodone levels at 3.4 hours versus 1.5 hours for immediate-release formulations. It acts directly on the cough center while the antihistamine component reduces histamine-mediated respiratory mucosal edema.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) signals defensive commercial strategy and smaller, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TUSSIONEX PENNKINETIC offers limited career growth given LOE approaching status and zero linked job openings. Roles are primarily maintenance and defensive, focused on managing generic transition rather than brand expansion. This is a consolidation position suitable for experienced professionals seeking stability in a declining asset.
Brand ManagerField Sales Representative
Worked on TUSSIONEX PENNKINETIC at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.